


# OUR PIPELINE

LAST UPDATED: JANUARY 5, 2024

We are building a pipeline of in vivo and ex vivo therapies, as well as continuing to develop innovative modular platform capabilities.

## IN VIVO PROGRAMS

**IN VIVO** CRISPR **is** the therapy  
**GENETIC DISEASES**



## EX VIVO PROGRAMS

**EX VIVO** CRISPR **creates** the therapy  
**IMMUNO-ONCOLOGY / AUTOIMMUNE DISEASE**



AATD: Alpha-1 Antitrypsin Deficiency

Lead refers to lead development and commercial party.

\* Intellia is advancing both wholly-owned and partnered programs.